Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

Xi Wang, Jing Ni, Chen Long Hsu, Sharlin Johnykutty, Ping Tang, Yuan Soon Ho, Chia Hwa Lee, Shuyuang Yeh

研究成果: 雜誌貢獻文章

14 引文 (Scopus)

摘要

We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.
原文英語
頁(從 - 到)971-977
頁數7
期刊Cancer Investigation
27
發行號10
DOIs
出版狀態已發佈 - 十一月 13 2009

指紋

Diphosphonates
Breast
Down-Regulation
Breast Neoplasms
Carcinoma
Carcinoma, Intraductal, Noninfiltrating
Prostate
Neoplasms
Colon
Carcinogenesis
Staining and Labeling
Kidney
Cell Line
Polymerase Chain Reaction
Lung
Liver
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

引用此文

Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer. / Wang, Xi; Ni, Jing; Hsu, Chen Long; Johnykutty, Sharlin; Tang, Ping; Ho, Yuan Soon; Lee, Chia Hwa; Yeh, Shuyuang.

於: Cancer Investigation, 卷 27, 編號 10, 13.11.2009, p. 971-977.

研究成果: 雜誌貢獻文章

Wang, Xi ; Ni, Jing ; Hsu, Chen Long ; Johnykutty, Sharlin ; Tang, Ping ; Ho, Yuan Soon ; Lee, Chia Hwa ; Yeh, Shuyuang. / Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer. 於: Cancer Investigation. 2009 ; 卷 27, 編號 10. 頁 971-977.
@article{c34053a038394c54a74e7e25b4fe99bf,
title = "Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer",
abstract = "We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57{\%} of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80{\%} in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.",
keywords = "BCa, TAP",
author = "Xi Wang and Jing Ni and Hsu, {Chen Long} and Sharlin Johnykutty and Ping Tang and Ho, {Yuan Soon} and Lee, {Chia Hwa} and Shuyuang Yeh",
year = "2009",
month = "11",
day = "13",
doi = "10.3109/07357900802392659",
language = "English",
volume = "27",
pages = "971--977",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

AU - Wang, Xi

AU - Ni, Jing

AU - Hsu, Chen Long

AU - Johnykutty, Sharlin

AU - Tang, Ping

AU - Ho, Yuan Soon

AU - Lee, Chia Hwa

AU - Yeh, Shuyuang

PY - 2009/11/13

Y1 - 2009/11/13

N2 - We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.

AB - We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.

KW - BCa

KW - TAP

UR - http://www.scopus.com/inward/record.url?scp=70450212895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450212895&partnerID=8YFLogxK

U2 - 10.3109/07357900802392659

DO - 10.3109/07357900802392659

M3 - Article

AN - SCOPUS:70450212895

VL - 27

SP - 971

EP - 977

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 10

ER -